[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
Bold
K O
KO
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D000077405:Irbesartan; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D011507:Proteinuria / Q000517:prevention & control*; D012307:Risk Factors; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan